Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 8;186(10):754-60.
doi: 10.1503/cmaj.130989. Epub 2014 Feb 18.

New treatments for metastatic melanoma

Craig Gedye  1 , David Hogg  1 , Marcus Butler  1 , Anthony M Joshua  2
Affiliations
Review

New treatments for metastatic melanoma

Craig Gedye et al. CMAJ. .
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
(A) Schematic of newly approved (solid lines) and experimental (dashed lines) treatments for patients with metastatic melanoma. The patient’s treatment is personalized according to the underlying driver mutation (e.g., NRAS-mutant in blue). (B) Historically, few treatments were available for melanoma. Examples of treatment progressions are shown for (C) patients with BRAF-mutant melanoma or (D) patients without an identifiable driver mutation (wild type). PD-1 = programmed cell death protein 1, PD-L1 = programmed cell death 1 ligand 1.
Figure 2:
Figure 2:
Immunotherapeutic antibodies target immune regulatory proteins on the surfaces of melanoma and lymphocyte cells (green), while kinase inhibitors (red) block mutated mitogen-activated protein kinase (MAPK) pathways. Traditional cytotoxic chemotherapy targets DNA replication (blue). CTLA-4 = cytotoxic T-lymphocyte–associated protein 4, ERK = extracellular signal-regulated kinase, MEK = mitogen-activated protein/ERK kinase, mTOR = mammalian target of rapamycin, PD-1 = programmed cell death protein 1, PD-L1 = programmed cell death 1 ligand 1.
Figure 3:
Figure 3:
Responses to BRAF inhibitors can be dramatic, but relapses are almost invariable and can be equally rapid. Abdominal computed tomographic scans showing peritoneal metastases (dashed white lines) before treatment (A), and after two months (B) and three months (C) of treatment with vemurafenib.
See this image and copyright information in PMC

References

    1. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;181:193–201 - PubMed
    1. Cebon J, Gedye C, John T, et al. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007;5:994–1006 - PubMed
    1. Halliday GM, Patel A, Hunt MJ, et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 1995;19:352–8 - PubMed
    1. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135–47 - PubMed
    1. Bauer J, Büttner P, Murali R, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24:345–51 - PMC - PubMed